File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020

TitleSerological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
Authors
Issue Date2020
PublisherEuropean Centre for Disease Prevention and Control. The Journal's web site is located at http://www.eurosurveillance.org/Public/AboutUs/AboutUs.aspx
Citation
Eurosurveillance, 2020, v. 25 n. 16, article no. 2000421 How to Cite?
AbstractBackground: The ongoing coronavirus disease (COVID-19) pandemic has major impacts on health systems, the economy and society. Assessing infection attack rates in the population is critical for estimating disease severity and herd immunity which is needed to calibrate public health interventions. We have previously shown that it is possible to achieve this in real time to impact public health decision making. Aim: Our objective was to develop and evaluate serological assays applicable in large-scale sero-epidemiological studies. Methods: We developed an ELISA to detect IgG and IgM antibodies to the receptor-binding domain (RBD) of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated its sensitivity and specificity in combination with confirmatory microneutralisation (MN) and 90% plaque reduction neutralisation tests (PRNT90) in 51 sera from 24 patients with virologically confirmed COVID-19 and in age-stratified sera from 200 healthy controls. Results: IgG and IgM RBD ELISA, MN and PRNT90 were reliably positive after 29 days from illness onset with no detectable cross-reactivity in age-stratified controls. We found that PRNT90 tests were more sensitive in detecting antibody than MN tests carried out with the conventional 100 tissue culture infectious dose challenge. Heparinised plasma appeared to reduce the infectivity of the virus challenge dose and may confound interpretation of neutralisation test. Conclusion: Using IgG ELISA based on the RBD of the spike protein to screen sera for SARS-CoV-2 antibody, followed by confirmation using PRNT90, is a valid approach for large-scale sero-epidemiology studies.
Persistent Identifierhttp://hdl.handle.net/10722/286613
ISSN
2015 SCImago Journal Rankings: 2.112
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorPerera, RAPM-
dc.contributor.authorMok, CKP-
dc.contributor.authorTsang, OTY-
dc.contributor.authorLv, H-
dc.contributor.authorKo, RLW-
dc.contributor.authorWu, NC-
dc.contributor.authorYuan, M-
dc.contributor.authorLeung, WS-
dc.contributor.authorChan, JMC-
dc.contributor.authorChik, TSH-
dc.contributor.authorChoi, CYC-
dc.contributor.authorLeung, K-
dc.contributor.authorChan, KH-
dc.contributor.authorChan, KCK-
dc.contributor.authorLi, KC-
dc.contributor.authorWu, JT-
dc.contributor.authorWilson, IA-
dc.contributor.authorMonto, AS-
dc.contributor.authorPoon, LLM-
dc.contributor.authorPeiris, M-
dc.date.accessioned2020-09-04T13:28:03Z-
dc.date.available2020-09-04T13:28:03Z-
dc.date.issued2020-
dc.identifier.citationEurosurveillance, 2020, v. 25 n. 16, article no. 2000421-
dc.identifier.issn1025-496X-
dc.identifier.urihttp://hdl.handle.net/10722/286613-
dc.description.abstractBackground: The ongoing coronavirus disease (COVID-19) pandemic has major impacts on health systems, the economy and society. Assessing infection attack rates in the population is critical for estimating disease severity and herd immunity which is needed to calibrate public health interventions. We have previously shown that it is possible to achieve this in real time to impact public health decision making. Aim: Our objective was to develop and evaluate serological assays applicable in large-scale sero-epidemiological studies. Methods: We developed an ELISA to detect IgG and IgM antibodies to the receptor-binding domain (RBD) of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated its sensitivity and specificity in combination with confirmatory microneutralisation (MN) and 90% plaque reduction neutralisation tests (PRNT90) in 51 sera from 24 patients with virologically confirmed COVID-19 and in age-stratified sera from 200 healthy controls. Results: IgG and IgM RBD ELISA, MN and PRNT90 were reliably positive after 29 days from illness onset with no detectable cross-reactivity in age-stratified controls. We found that PRNT90 tests were more sensitive in detecting antibody than MN tests carried out with the conventional 100 tissue culture infectious dose challenge. Heparinised plasma appeared to reduce the infectivity of the virus challenge dose and may confound interpretation of neutralisation test. Conclusion: Using IgG ELISA based on the RBD of the spike protein to screen sera for SARS-CoV-2 antibody, followed by confirmation using PRNT90, is a valid approach for large-scale sero-epidemiology studies.-
dc.languageeng-
dc.publisherEuropean Centre for Disease Prevention and Control. The Journal's web site is located at http://www.eurosurveillance.org/Public/AboutUs/AboutUs.aspx-
dc.relation.ispartofEurosurveillance-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleSerological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020-
dc.typeArticle-
dc.identifier.emailPerera, RAPM: mahenp@hku.hk-
dc.identifier.emailMok, CKP: ch02mkp@hkucc.hku.hk-
dc.identifier.emailLeung, K: ksmleung@hku.hk-
dc.identifier.emailChan, KH: ra98466@hku.hk-
dc.identifier.emailChan, KCK: karlcck@hku.hk-
dc.identifier.emailLi, KC: kc109698@hku.hk-
dc.identifier.emailWu, JT: joewu@hku.hk-
dc.identifier.emailPoon, LLM: llmpoon@hkucc.hku.hk-
dc.identifier.emailPeiris, M: malik@hkucc.hku.hk-
dc.identifier.authorityPerera, RAPM=rp02500-
dc.identifier.authorityMok, CKP=rp01805-
dc.identifier.authorityLeung, K=rp02563-
dc.identifier.authorityWu, JT=rp00517-
dc.identifier.authorityPoon, LLM=rp00484-
dc.identifier.authorityPeiris, M=rp00410-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.2807/1560-7917.ES.2020.25.16.2000421-
dc.identifier.pmid32347204-
dc.identifier.pmcidPMC7189648-
dc.identifier.scopuseid_2-s2.0-85084187174-
dc.identifier.hkuros314055-
dc.identifier.volume25-
dc.identifier.issue16-
dc.identifier.spagearticle no. 2000421-
dc.identifier.epagearticle no. 2000421-
dc.identifier.isiWOS:000528319500003-
dc.publisher.placeSweden-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats